DK1621198T3 - Substituerede carbostyrilderivater som 5-HT1A-receptorsubtype-agonister - Google Patents

Substituerede carbostyrilderivater som 5-HT1A-receptorsubtype-agonister

Info

Publication number
DK1621198T3
DK1621198T3 DK05023971T DK05023971T DK1621198T3 DK 1621198 T3 DK1621198 T3 DK 1621198T3 DK 05023971 T DK05023971 T DK 05023971T DK 05023971 T DK05023971 T DK 05023971T DK 1621198 T3 DK1621198 T3 DK 1621198T3
Authority
DK
Denmark
Prior art keywords
receptor subtype
ht1a receptor
carbostyril derivatives
subtype agonists
substituted carbostyril
Prior art date
Application number
DK05023971T
Other languages
Danish (da)
English (en)
Inventor
Yasufumi Uwahodo
Shaun Jordan
Tetsuro Kikuchi
Katsura Tottori
Tsuyoshi Hirose
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25087808&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1621198(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Application granted granted Critical
Publication of DK1621198T3 publication Critical patent/DK1621198T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK05023971T 2001-01-29 2002-01-29 Substituerede carbostyrilderivater som 5-HT1A-receptorsubtype-agonister DK1621198T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77021001A 2001-01-29 2001-01-29
PCT/JP2002/000626 WO2002060423A2 (en) 2001-01-29 2002-01-29 Substituted carbostyril derivatives as 5-ht1a receptor subtype agonists

Publications (1)

Publication Number Publication Date
DK1621198T3 true DK1621198T3 (da) 2007-09-24

Family

ID=25087808

Family Applications (3)

Application Number Title Priority Date Filing Date
DK02716434T DK1355639T3 (da) 2001-01-29 2002-01-29 Substituerede carbostyrilderivater som 5-HT1A-receptorsubtypeagonister
DK06015782.3T DK1712225T3 (da) 2001-01-29 2002-01-29 Substituered carbostyril-derivater som agonister af receptorundertype 5-HT 1A til behandling af bipolar lidelse
DK05023971T DK1621198T3 (da) 2001-01-29 2002-01-29 Substituerede carbostyrilderivater som 5-HT1A-receptorsubtype-agonister

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK02716434T DK1355639T3 (da) 2001-01-29 2002-01-29 Substituerede carbostyrilderivater som 5-HT1A-receptorsubtypeagonister
DK06015782.3T DK1712225T3 (da) 2001-01-29 2002-01-29 Substituered carbostyril-derivater som agonister af receptorundertype 5-HT 1A til behandling af bipolar lidelse

Country Status (20)

Country Link
EP (3) EP1621198B1 (xx)
JP (4) JP4178032B2 (xx)
KR (5) KR100825705B1 (xx)
CN (3) CN1239154C (xx)
AR (4) AR032641A1 (xx)
AT (3) ATE322894T1 (xx)
AU (4) AU2002226752C1 (xx)
BR (1) BR0206237A (xx)
CA (2) CA2429496C (xx)
CY (3) CY1105631T1 (xx)
DE (3) DE60239711D1 (xx)
DK (3) DK1355639T3 (xx)
ES (3) ES2286755T3 (xx)
HK (2) HK1061805A1 (xx)
MX (2) MX344556B (xx)
MY (1) MY129355A (xx)
PH (1) PH12014500937A1 (xx)
PT (3) PT1355639E (xx)
TW (2) TWI331919B (xx)
WO (1) WO2002060423A2 (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
DE10148233A1 (de) * 2001-09-28 2003-04-10 Boehringer Ingelheim Pharma Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme
EP1551393A4 (en) * 2002-07-30 2010-06-16 Peter Migaly COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS
AR042806A1 (es) * 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
AU2003295235B2 (en) * 2002-12-27 2008-06-19 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
DK1626721T3 (en) * 2003-05-23 2017-01-23 Otsuka Pharma Co Ltd CARBOSTYRIL DERIVATIVES AND Mood Stabilizers for the Treatment of Mood Disorders
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
FR2865650B1 (fr) * 2004-01-30 2008-06-13 Biocortech Utilisation du 14,15 dihydro 20,21-dinoreburnamenin14-ol pour traiter et/ou prevenir les depressions majeures et les desordres du cycle veille-sommeil
WO2006090273A2 (en) * 2005-02-22 2006-08-31 Warner-Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
EP1912650B8 (en) * 2005-08-03 2017-10-18 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
TW200848041A (en) * 2007-03-30 2008-12-16 Otsuka Pharma Co Ltd A medicament for treating schizophrenia comprising cilostazol
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
JP2009286740A (ja) * 2008-05-30 2009-12-10 Otsuka Pharmaceut Co Ltd アリピプラゾールを含有する逆耐性抑制剤
EP2338873A1 (en) 2009-12-22 2011-06-29 Gmeiner, Peter New aminotetraline derivatives
AR090245A1 (es) 2012-03-06 2014-10-29 Otsuka Pharma Co Ltd Preparacion solida oral de liberacion sostenida, metodo de preparacion
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPS5646812A (en) * 1979-09-27 1981-04-28 Otsuka Pharmaceut Co Ltd Central nervous system depressant
DE3721799C2 (de) 1986-07-01 1993-12-23 Mitsubishi Electric Corp Integrierte Redox-Bauelementschaltung und Verfahren zum Herstellen
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
AU1928792A (en) * 1991-05-20 1992-12-30 Upjohn Company, The Carboxamido-(1,2n)-carbocyclic-2-aminotetralin derivatives
US5532240A (en) * 1991-12-26 1996-07-02 Yoshitomi Pharmaceutical Industries, Ltd. Condensed thiophene compound and pharmaceutical use thereof
AU5446894A (en) * 1992-10-23 1994-05-24 New York University Functional interactions between glial s-100b and central nervous system serotonergic neurons
DK148292D0 (da) * 1992-12-09 1992-12-09 Lundbeck & Co As H Forbindelser
JP2959615B2 (ja) * 1993-06-24 1999-10-06 吉富製薬株式会社 縮合型チオフェン化合物およびその医薬用途
JPH09291034A (ja) * 1996-02-27 1997-11-11 Yoshitomi Pharmaceut Ind Ltd 縮合ピリジン化合物およびその医薬としての用途
US5688950A (en) * 1996-04-23 1997-11-18 Neurogen Corporation Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands
CA2252895C (en) * 1996-05-07 2002-08-20 Pfizer Inc. Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (=ziprasidone), its preparation and its use as dopamine d2 antagonist
JP4012994B2 (ja) * 1996-05-08 2007-11-28 大塚製薬株式会社 抗不安薬
JP2000516936A (ja) * 1996-08-27 2000-12-19 アメリカン・ホーム・プロダクツ・コーポレイション ドパミンｄ２作動薬としておよび５―ｈｔ１ａリガンドとしての４―アミノエトキシインドール
WO1999038864A1 (en) * 1998-02-03 1999-08-05 American Home Products Corporation Oxazole derivatives as serotonin-1a receptor agonists
AU3555099A (en) * 1998-04-13 1999-11-01 American Home Products Corporation 4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists
JPH11335286A (ja) * 1998-05-25 1999-12-07 Mitsui Chem Inc ドーパミン拮抗薬の効果増強剤
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
SI1627639T1 (sl) * 2001-06-19 2010-04-30 Mueller Norbert Uporaba inhibitorjev COX-2 za zdravljenje afektivnih motenj
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma

Also Published As

Publication number Publication date
AU2007201701A1 (en) 2007-05-10
CN1239154C (zh) 2006-02-01
KR100653591B1 (ko) 2006-12-05
EP1355639B1 (en) 2006-04-12
ATE322894T1 (de) 2006-04-15
MY129355A (en) 2007-03-30
TWI331919B (en) 2010-10-21
CA2429496A1 (en) 2002-08-08
DE60210581D1 (en) 2006-05-24
EP1621198A3 (en) 2006-04-12
AU2007201701B2 (en) 2010-06-17
AU2002226752B2 (en) 2005-03-17
EP1355639A2 (en) 2003-10-29
EP1712225A1 (en) 2006-10-18
JP4896831B2 (ja) 2012-03-14
PT1355639E (pt) 2006-06-30
KR20060085260A (ko) 2006-07-26
WO2002060423A3 (en) 2003-04-10
KR100713607B1 (ko) 2007-05-02
AU2009233591A1 (en) 2009-11-19
ES2261652T3 (es) 2006-11-16
AU2005201772B2 (en) 2007-05-17
CY1108031T1 (el) 2013-09-04
AR032641A1 (es) 2003-11-19
MX344556B (es) 2016-12-20
AR079761A2 (es) 2012-02-15
AU2009233591B2 (en) 2011-10-20
CN100450485C (zh) 2009-01-14
JP2007297405A (ja) 2007-11-15
EP1621198B1 (en) 2007-05-23
KR100601073B1 (ko) 2006-07-19
EP1621198A2 (en) 2006-02-01
EP1712225B1 (en) 2011-04-06
AR099754A2 (es) 2016-08-17
KR100763288B1 (ko) 2007-10-04
KR20070065425A (ko) 2007-06-22
DE60220325T2 (de) 2008-01-17
KR20060028485A (ko) 2006-03-29
CY1111392T1 (el) 2015-08-05
ATE504293T1 (de) 2011-04-15
JP4178032B2 (ja) 2008-11-12
ES2363366T3 (es) 2011-08-02
KR100825705B1 (ko) 2008-04-29
TW200522960A (en) 2005-07-16
AU2002226752C1 (en) 2010-02-18
KR20030065570A (ko) 2003-08-06
DK1712225T3 (da) 2011-06-20
PT1621198E (pt) 2007-06-08
CN1484524A (zh) 2004-03-24
AU2005201772C1 (en) 2010-06-03
KR20050107822A (ko) 2005-11-15
HK1091403A1 (en) 2007-01-19
CN1879624A (zh) 2006-12-20
BR0206237A (pt) 2003-12-23
CA2700314C (en) 2012-04-24
JP2011225587A (ja) 2011-11-10
DK1355639T3 (da) 2006-08-14
PT1712225E (pt) 2011-04-18
HK1061805A1 (en) 2004-10-08
JP2004517937A (ja) 2004-06-17
ATE362763T1 (de) 2007-06-15
TWI302832B (en) 2008-11-11
JP2011184460A (ja) 2011-09-22
PH12014500937A1 (en) 2015-09-21
CY1105631T1 (el) 2010-12-22
WO2002060423A2 (en) 2002-08-08
DE60220325D1 (de) 2007-07-05
CN1813745A (zh) 2006-08-09
AR080849A2 (es) 2012-05-09
JP5683010B2 (ja) 2015-03-11
DE60239711D1 (de) 2011-05-19
CA2429496C (en) 2010-10-19
AU2005201772A1 (en) 2005-05-19
ES2286755T3 (es) 2007-12-01
DE60210581T2 (de) 2007-04-05
CA2700314A1 (en) 2002-08-08
MXPA03006603A (es) 2004-02-12

Similar Documents

Publication Publication Date Title
DK1355639T3 (da) Substituerede carbostyrilderivater som 5-HT1A-receptorsubtypeagonister
DK1446379T3 (da) Arylanilin-beta2-adrenergiske receptoragonister
DK1385825T3 (da) Substituerede 2-pyridincyclohexan-1,4-diaminderivater
NO20044654L (no) Piperidinoylpiperidiner som 5-HTIF-agonister
NO20052797D0 (no) Fenyl eller heteroaryl aminoalkanderivater som IP-reseptorantagonister
DK1309559T3 (da) 4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister
PL370408A1 (en) New sulfonamide derivatives as d3-receptor agonists
DK1414440T3 (da) N-phenylpyrrolguanidinderivater som melanocortinreceptorligander
DK1735304T3 (da) Quinolinoncarboxamidforbindelser som 5-HT4-receptoragonister
DK1049689T3 (da) 4-(2-keto-1-benzimidazolinyl)piperidinderivater som ORL1-receptoragonister
DK1317442T3 (da) Quinolinonderivater som tyrosinkinaseinhibitorer
NO20041235L (no) Kinolinderivater som neuropeptid Y antagonister
NO20043022L (no) 5,6-diaryl-pyrazin-2-amid-derivater som CB1-antagonister
ATE377419T1 (de) Substituierte 4-alkoxyoxazol derivate als ppar agonisten
DK1499316T3 (da) (1-4-piperidinyl)benzimidazolderivater anvendelige som histamin-H3-antagonister
NO20021459L (no) Piperazin-derivater som 5-HT1B-antagonister
NO20032142L (no) Substituerte 2-fenylaminoimidazolin-fenylketon-derivater som IP-antagonister
DK1305319T3 (da) 4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister
ATE492535T1 (de) 4-piperidinylalkylamin-derivate, antagonisten von muscarinrezeptoren
DE60214408D1 (de) 5-METHOXY-8-ARYL-i1,2,4öTRIAZOLOi1,5-AöPYRIDINE DERIVATIVE ALS ADENOSIN-REZEPTOR ANTAGONISTEN
DE60210058D1 (de) Alkoxycarbonylamino-heteroaryl-carbonsäurederivate als ip-antagonisten
DK1406888T3 (da) Substituerede gamma-lactonforbindelser som NMDA-antagonister
NO20023380L (no) Indolderivater som MCP-1-reseptoragonister
DK1390351T3 (da) Pyrimidinderivater, der er nyttige som selektive COX-2-inhibitorer
IS2431B (is) Nýjar indólafleiður